Takeda Gmbh

Other

Bayer Schering Pharma Ag

Altana Pharma Ag

Josef Stadlwieser

Beate Schmidt

Torsten Dunkern

Heiko Bernsmann

Andreas Pahl

Ewald Benediktus

Ragna Hussong

Alexander Sudau

Robert Huber

Luis Moroder

Thomas Martin

Wolfram Bode

Wolf-R&uuml;diger Ulrich

Thomas B&auml;r

Ulrich Thibaut

Christian Sommerhoff

Rolf Beume

Matthias Mueller

Olaf Nimz

Norbert Schaschke

Andreas Bergner

Pedro Jose Barbosa Pereira

Andreas Dominik

Karl-Josef Goebel

Daniela Bundschuh

Thomas Maier

Thomas Beckers

Geert Jan Sterk

Gerhard Grundler

Armin Hatzelmann

Degenhard Marx

Thomas Baer

Ulrich Graedler

Steffen Weinbrenner

Thomas Ciossek

Armin Zuelch

Jörg Diefenbach

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.

Methylpyrrolopyrimidinecarboxamides

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

The compounds of Formula (I), wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Methylpyrrolopyridinecarboxamides

The compounds of Formula (I), in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines

The invention relates to novel pyrimidine derivatives of Formula (1) which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.

4,6-disubstituted pyrimidines and their use as protein kinase inhibitors

3,4-Dihydroisoquinoline and isoquinoline compounds of formula I, in which Ar represents a phenyl raidcal of the formulae IIa, IIb or IIc are novel effective PDE7 inhibitors.

(Dihydro) isoquinoline derivatives as phosphodiesterase inhibitors

Tryptase inhibitors

The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.

Growing community of inventors

Constance, Germany

Josef Stadlwieser